Anna-Karin Areskog is working on pHyph achieving the CE mark. Credit: Fotograf / Gedea Biotech.

Swedish women’s health company Gedea Biotech has announced the appointment of Anna-Karin Areskog as QA Director.

She has experience from previous positions as QA/RA and senior QA manager in the pharmaceutical and mainly in medical device industries covering regulations, quality standards and guidelines such as 21 CFR 820, ISO13485, MDR, GMP and IVDR.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Additionally, the company has announced the approval of its ISO13485 re-certification.

It stated that these developments serve as key milestones to achieve CE marking for pHyph, an antibiotic-free treatment for bacterial vaginosis (BV).

Anna-Karin Areskog said: “I am passionate about contributing to small innovative companies like Gedea with my experience.

“Realising the large unmet need for Gedea’s product pHyph for relieving symptoms and preventing recurrence of bacterial vaginosis, I am so proud to be part of the development work.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

pHyph is a vaginal tablet that has been developed to treat BV and prevent a recurrence.

It restores the vaginal pH to its natural level, removes the infectious bacterial build-up of biofilm formed during BV, restricts the infectious bacteria growth and restores the healthy vaginal microbiome.

Together, these mechanisms of action provide a beneficial environment for a healthy vaginal microbiome.

In a clinical trial, 90% of patients treated with pHyph had symptom reduction and 70% of them had an absence of symptoms by day seven.

The vaginal tablet demonstrated excellent medical effect, with 50.4% of the patients clinically cured of BV by day seven.